Contemporary HIV-1 consensus Env with AI-assisted redesigned hypervariable loops promote antibody binding
-
Published:2024-05-09
Issue:1
Volume:15
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Bai HongjunORCID, Lewitus EricORCID, Li YifanORCID, Thomas Paul V.ORCID, Zemil MichelleORCID, Merbah Mélanie, Peterson Caroline E., Thuraisamy Thujitha, Rees Phyllis A., Hajduczki Agnes, Dussupt VincentORCID, Slike BonnieORCID, Mendez-Rivera Letzibeth, Schmid Annika, Kavusak Erin, Rao Mekhala, Smith Gabriel, Frey JessicaORCID, Sims AliceaORCID, Wieczorek Lindsay, Polonis Victoria, Krebs Shelly J.ORCID, Ake Julie A., Vasan SandhyaORCID, Bolton Diane L.ORCID, Joyce M. Gordon, Townsley Samantha, Rolland MorganeORCID
Abstract
AbstractAn effective HIV-1 vaccine must elicit broadly neutralizing antibodies (bnAbs) against highly diverse Envelope glycoproteins (Env). Since Env with the longest hypervariable (HV) loops is more resistant to the cognate bnAbs than Env with shorter HV loops, we redesigned hypervariable loops for updated Env consensus sequences of subtypes B and C and CRF01_AE. Using modeling with AlphaFold2, we reduced the length of V1, V2, and V5 HV loops while maintaining the integrity of the Env structure and glycan shield, and modified the V4 HV loop. Spacers are designed to limit strain-specific targeting. All updated Env are infectious as pseudoviruses. Preliminary structural characterization suggests that the modified HV loops have a limited impact on Env’s conformation. Binding assays show improved binding to modified subtype B and CRF01_AE Env but not to subtype C Env. Neutralization assays show increases in sensitivity to bnAbs, although not always consistently across clades. Strikingly, the HV loop modification renders the resistant CRF01_AE Env sensitive to 10-1074 despite the absence of a glycan at N332.
Funder
Henry M. Jackson Foundation
Publisher
Springer Science and Business Media LLC
Reference99 articles.
1. Mascola, J. R. & Montefiori, D. C. The role of antibodies in HIV vaccines. Annu. Rev. Immunol. 28, 413–444 (2010). 2. Saunders, K. O., Rudicell, R. S. & Nabel, G. J. The design and evaluation of HIV-1 vaccines. AIDS Lond. Engl. 26, 1293–1302 (2012). 3. Wibmer, C. K., Moore, P. L. & Morris, L. HIV broadly neutralizing antibody targets. Curr. Opin. HIV AIDS 10, 135–143 (2015). 4. Kwong, P. D. & Mascola, J. R. HIV-1 vaccines based on antibody identification, B cell ontogeny, and epitope structure. Immunity 48, 855–871 (2018). 5. Sok, D. & Burton, D. R. Recent progress in broadly neutralizing antibodies to HIV. Nat. Immunol. 19, 1179–1188 (2018).
|
|